Koetting Cecelia, Schweitzer Justin, Nichols Kelly K, McDonald Marguerite, Starr Christopher E, Chan Clara C, Brujic Mile, Racine Louis, Mah Francis S, Barnett Melissa, Farid Marjan, Donnenfeld Eric D, Mercado Carolina, Ratay Michelle, Cavet Megan, Ryan Robert, Fain Joel, Feulner Lisa K
University of Colorado School of Medicine, Aurora, CO, USA.
Vance Thompson Vision, Sioux Falls, SD, USA.
Ophthalmol Ther. 2025 Jul 10. doi: 10.1007/s40123-025-01190-3.
Lifitegrast ophthalmic solution 5% is indicated to treat signs and symptoms of dry eye disease (DED). This study assessed eyecare professionals' (ECPs) real-world experiences with lifitegrast in DED.
A total of 12 ECPs (6 ophthalmologists and 6 optometrists) with experience prescribing lifitegrast completed a cross-sectional survey on practice characteristics, lifitegrast utilization, satisfaction, and adverse events (AEs). ECPs rated satisfaction with lifitegrast overall and for specific clinical outcomes versus other prescription eye drops on a 1 (very dissatisfied) to 10 (very satisfied) Likert scale.
ECPs reported a mean of 1288 (range, 35-6000) patients with DED treated annually, with 20.9% receiving lifitegrast. Overall, 66.7% of ECPs reported near/complete symptom resolution in patients after 1-3 months of lifitegrast treatment. Mean (range) satisfaction ratings for onset/effectiveness were 6.8 (3-9)/6.6 (3-9). Satisfaction with reduction of DED signs was generally high: increased tear film breakup time, 5.8 (3-9); reduced conjunctival/corneal staining, 6.9 (3-9); increased Schirmer test score, 6.0 (3-9); increased tear meniscus height, 6.0 (3-9); and reduced Ocular Surface Disease Index severity, 7.0 (3-10). Symptom reduction satisfaction ratings were: itching, 5.3 (1-9); dryness, 6.9 (3-9); burning/stinging, 6.3 (1-9); redness, 6.2 (4-9); pain, 6.3 (3-9); light sensitivity, 6.5 (3-9); and blurred/poor vision, 6.8 (4-9). Overall satisfaction (ECPs/patients) was rated 7.1 (3-10)/6.8 (2-9). Predominant uses of lifitegrast included contact lens-induced DED (91.7%) and DED before/after refractive or cataract surgery (83.3% each). AEs reported were consistent with the known AE profile of lifitegrast and included burning/stinging, blurred vision, and dysgeusia.
This real-world survey showed that ECPs use lifitegrast to treat one fifth of their patients with DED and reported moderate-to-high personal and patient satisfaction with lifitegrast treatment.
5%的lifitegrast眼药水被用于治疗干眼症（DED）的体征和症状。本研究评估了眼科护理专业人员（ECP）在治疗DED中使用lifitegrast的实际经验。
共有12名有使用lifitegrast处方经验的ECP（6名眼科医生和6名验光师）完成了一项关于执业特点、lifitegrast使用情况、满意度和不良事件（AE）的横断面调查。ECP对lifitegrast总体以及与其他处方眼药水相比的特定临床结果的满意度进行评分，采用1（非常不满意）至10（非常满意）的李克特量表。
ECP报告每年平均治疗1288名（范围35 - 6000名）DED患者，其中20.9%接受lifitegrast治疗。总体而言，66.
